Recent advances in novel radioimmunotherapeutic approaches for allogeneic hematopoietic cell transplantation.

Publication Type:

Journal Article


Current opinion in oncology, Volume 22, Issue 2, p.143-9 (2010)


2010, Biologics Production Core Facility, Cell Processing Core Facility, Center-Authored Paper, Clinical Research Division, Clinical Trials as Topic, Comparative Medicine Core Facility, Flow Cytometry Core Facility, Genomics Core Facility, Hematologic Neoplasms, hematopoietic stem cell transplantation, Humans, Proteomics Core Facility, Radioimmunotherapy, Shared Resources, Transplantation, Homologous


Allogeneic hematopoietic cell transplantation (HCT) can be a curative treatment for hematologic malignancies and over the last three decades, novel approaches have resulted in significant reductions in morbidity and mortality. Despite current advances, two major limitations remain: patients continue to die from recurrent disease, and rates of nonrelapse mortality are relatively high due to regimen-related organ toxicities. The ability to target therapy with radiolabeled antibodies provides an innovative way to increase the tumoricidal dose of radiation to tumor sites, whereas sparing normal organs, as further dose escalation of chemotherapy and radiotherapy in HCT preparative regimens is not feasible due to dose-limiting toxicities.